A notable finding was the relatively stronger interaction with the histamine H3 receptor (H3R, −5.07 kcal mol−1), a less conventional but emerging target in hormone-responsive cancers like prostate cancer. This evidence concerns the gene HRH3 and prostate carcinoma.